Aesrx Seeks to Solve Sickle Cell Disease Puzzle
Five years after its launch, virtual biotech Aesrx LLC has advanced a small molecule anti-sickling agent into a Phase II trial in patients with sickle cell disease (SCD) – and done so without a venture capital round. If the compound proves its mettle, the company could become the first to market a treatment that directly blocks cell sickling rather than seeking simply to reduce the frequency of sickle cell crises.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter